Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
Atsushi Nakajima(Yokohama City University), Michael Camilleri(CSIRO Manufacturing), Jan P. Mattsson(Novartis (Switzerland)), Per-Göran Gillberg, Mitsunori Seki(EA Pharma (Japan)), Akira Ohta(Shinshu University), Shinya Taniguchi(Konan University)
Cited by 174
Related Papers
Functional Gastroduodenal Disorders
|Gastroenterology|2006|2.4k
Intestinal barrier function in health and gastrointestinal disease
|Neurogastroenterology & Motility|2012|886
Laboratory characterisation of coal reservoir permeability for primary and enhanced coalbed methane recovery
|International Journal of Coal Geology|2009|477